• Issue

    American Journal of Hematology: Volume 99, Issue 8

    1447-1660
    August 2024
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

ISSUE INFORMATION

Free Access

Issue Information

  • Pages: 1447-1449
  • First Published: 08 July 2024

EDITORIAL AND COMMENTARY

Aspirin use in essential thrombocythemia: Once-daily or twice-daily or not at all?

Ayalew Tefferi,  Tiziano Barbui, 
  • Pages: 1450-1453
  • First Published: 16 May 2024
Aspirin use in essential thrombocythemia: Once-daily or twice-daily or not at all?

Asprin dosing strategy in low risk (young and JAK2 mutated without history of thrombosis) or very low risk (young JAK2 wild-type without history of thrombosis) essential thrombocythemia.

Paving the path for ongoing clinical research and education in post retirement age

Tiziano Barbui, 
  • Pages: 1454-1455
  • First Published: 17 May 2024

Improving healthspan among people with sickle cell disease: Leveraging precision health in an era of treatments with curative intent

Elaine A. Yu,  Helena U. Zacharias,  Shannon Kelly,  Elliott Vichinsky, 
  • Pages: 1456-1458
  • First Published: 16 May 2024

Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?

Ayalew Tefferi,  Animesh Pardanani,  Naseema Gangat, 
  • Pages: 1459-1461
  • First Published: 20 May 2024

RESEARCH ARTICLE

Open Access

Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial

Bianca Rocca,  Alberto Tosetto,  Giovanna Petrucci,  Elena Rossi,  Silvia Betti,  Denise Soldati,  Alessandra Iurlo,  Daniele Cattaneo,  Cristina Bucelli,  Alfredo Dragani,  Mauro Di Ianni,  Paola Ranalli,  Francesca Palandri,  Nicola Vianelli,  Eloise Beggiato,  Giuseppe Lanzarone,  Marco Ruggeri,  Giuseppe Carli,  Elena Maria Elli,  Rossella Renso,  Maria Luigia Randi,  Irene Bertozzi,  Giuseppe Gaetano Loscocco,  Alessandra Ricco,  Giorgina Specchia,  Alessandro M. Vannucchi,  Francesco Rodeghiero,  Valerio De Stefano,  Carlo Patrono,  for the Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators , 
  • Pages: 1462-1474
  • First Published: 15 June 2024
Open Access

Cost-effectiveness of sutimlimab in cold agglutinin disease

Satoko Ito,  Daniel Wang,  Adriana Purcell,  Karthik Chetlapalli,  Alfred I. Lee,  Adam Cuker,  George Goshua, 
  • Pages: 1475-1484
  • First Published: 11 May 2024
Cost-effectiveness of sutimlimab in cold agglutinin disease

Sutimlimab is cost-ineffective at current pricing, regardless of dosing and even when compared to pan-refractory standard of care with intensive therapy, over short- and long-run time-horizons. Significant price reduction (>80%) or time-limited treatment (<18 months, if followed by lifelong remission) would allow sutimlimab to become cost-effective in the United States.

Open Access

Management of post-autologous transplant relapse in patients with T-cell lymphomas

Olivier Veilleux,  Francisco Socola,  Sally Arai,  Matthew J. Frank,  Laura Johnston,  Robert Lowsky,  Judith Shizuru,  Everett Meyer,  Lori Muffly,  Andrew R. Rezvani,  Parveen Shiraz,  Surbhi Sidana,  Saurabh Dahiya,  David B. Miklos,  Robert S. Negrin,  Wen-Kai Weng, 
  • Pages: 1485-1491
  • First Published: 25 April 2024
Management of post-autologous transplant relapse in patients with T-cell lymphomas

Brentuximab vedotin and allogeneic transplant provides long term survival in relapsed PTCL patients after AHCT.

Open Access

High prevalence of iron deficiency and socioeconomic disparities in laboratory screening of non-pregnant females of reproductive age: A retrospective cohort study

Sophia Wen,  Rosane Nisenbaum,  Angela C. Weyand,  Grace H. Tang,  Michael Auerbach,  Michelle Sholzberg, 
  • Pages: 1492-1499
  • First Published: 02 May 2024
Open Access

Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry

Pramod K. Mistry,  Manisha Balwani,  Joel Charrow,  Jeremy Lorber,  Claus Niederau,  Jenny L. Carwile,  Antonio Oliveira-dos-Santos,  Maria Gabriela Perichon,  Sefika Uslu Cil,  Priya S. Kishnani, 
  • Pages: 1500-1510
  • First Published: 30 April 2024
Open Access

Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients

Roberta Marra,  Antonella Nostroso,  Barbara Eleni Rosato,  Federica Maria Esposito,  Vanessa D'Onofrio,  Anthony Iscaro,  Antonella Gambale,  Barbara Bruschi,  Paola Coccia,  Antonella Poloni,  Sule Unal,  Alberto Romano,  Achille Iolascon,  Immacolata Andolfo,  Roberta Russo, 
  • Pages: 1511-1522
  • First Published: 26 April 2024
Open Access

Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study

Elisabeth Dovern,  Mesire Aydin,  Mette D. Hazenberg,  Man Wai Tang,  Elisabeth M. Suijk,  Gerianne M. Hoogendoorn,  Charlotte F. J. Van Tuijn,  Jean-Louis Kerkhoffs,  Caroline E. Rutten,  Sacha S. Zeerleder,  Josu de la Fuente,  Bart J. Biemond,  Erfan Nur, 
  • Pages: 1523-1531
  • First Published: 11 May 2024
Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study

Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: a prospective observational cohort study.

Open Access

Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma

Shaji Kumar,  S. Vincent Rajkumar,  Dragan Jevremovic,  Robert A. Kyle,  Yulia Shifrin,  Michelle Nguyen,  Zahabiya Husain,  Asieh Alikhah,  Anita Jafari,  Sabine Mai,  Kenneth Anderson,  Sherif Louis, 
  • Pages: 1532-1539
  • First Published: 15 May 2024
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma

We analyzed 168 patients with smoldering multiple myeloma (SMM). We achieved an AUC of 0.8 in ROC analysis, with a positive predictive value of 85% and a negative predictive value of 73%. Our sensitivity and specificity were 83% and 76%, respectively. These results highlight the efficacy of telomere profiling as an independent biomarker for stratifying SMM patients into risk groups with high sensitivity and specificity.

Open Access

Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation

Nico Gagelmann,  Claudia Schuh,  Sarah Flossdorf,  Desiree Kunadt,  Matthias Stelljes,  Igor W. Blau,  Arne Brecht,  Wolfgang Bethge,  Thomas Schroeder,  Gerald Wulf,  Elisa Sala,  Gesine Bug,  Katharina Fleischhauer,  Nicolaus Kröger, on behalf of the German Registry for Stem Cell Transplantation, DRST , 
  • Pages: 1540-1549
  • First Published: 14 May 2024
Open Access

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia

Paola Guglielmelli,  Barbara Mora,  Francesca Gesullo,  Francesco Mannelli,  Giuseppe Gaetano Loscocco,  Leonardo Signori,  Chiara Pessina,  Ilaria Colugnat,  Raffaela Aquila,  Manjola Balliu,  Chiara Maccari,  Simone Romagnoli,  Chiara Paoli,  Elena Nacca,  Lorenzo Fagiolo,  Margherita Maffioli,  Tiziano Barbui,  Francesco Passamonti,  Alessandro M. Vannucchi, 
  • Pages: 1550-1559
  • First Published: 06 June 2024

CRITICAL REVIEW

High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy

Matthew J. Rees,  Shaji Kumar, 
  • Pages: 1560-1575
  • First Published: 13 April 2024

Ponatinib-review of historical development, current status, and future research

Hagop M. Kantarjian,  Helen T. Chifotides,  Fadi G. Haddad,  Nicholas J. Short,  Sanam Loghavi,  Elias Jabbour, 
  • Pages: 1576-1585
  • First Published: 10 May 2024

ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES

Free Access

Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management

Andres Ramirez-Gamero,  Humberto Martínez-Cordero,  Brady E. Beltrán,  Jorge Florindez,  Luis Malpica,  Jorge J. Castillo, 
  • Pages: 1586-1594
  • First Published: 20 May 2024

CLINICAL PEARLS IN BLOOD DISEASES

MORPHOLOGY UPDATE

Open Access

From the eosinophil to a novel FGFR1 fusion gene

Kirsteen Harper,  Gillian Horne,  Mike Leach,  Barbara J. Bain, 
  • Pages: 1595-1596
  • First Published: 23 February 2024

IMAGES IN HEMATOLOGY

Plasmablastic lymphoma in the pleural cavity

Aditi Manjeri,  Shir Ying Lee,  Siok-Bian Ng,  Chun-Tsu Lee, 
  • Pages: 1597-1598
  • First Published: 01 June 2024

NPM1-mutated myeloid neoplasm with low percentage of blasts

Brunangelo Falini,  Patrizia Chiusolo,  Luana Fianchi,  Livio Pagano, 
  • Pages: 1599-1600
  • First Published: 23 February 2024

CORRESPONDENCE

Free Access

High risk of progression for chronic major organ complications of sickle cell disease in adolescents and young adults: A long-term neonatal cohort study

Marion Borgey,  Isabelle Genty,  Anoosha Habibi,  Jean-Benoit Arlet,  Nathalie Dhedin,  François Lionnet,  Emmanuelle Bernit,  Maryse Etienne Julan,  Gylna Loko,  Cécile Arnaud,  Annie Kamdem,  Serge Pissard,  Eric Guémas,  Clara Noizat,  Corinne Pondarré, 
  • Pages: 1601-1605
  • First Published: 30 April 2024
Free Access

Long-term follow-up of children with sickle cell disease diagnosed by newborn screening in the Netherlands: Overview of morbidity and mortality

Caroline Vuong,  Corien L. Eckhardt,  Harriët Heijboer,  Monique H. Suijker,  Lydian A. de Ligt,  Aimee L.A. Voigt,  Mariska M. G. Leeflang,  Marije Bartels,  Paul Brons,  Louise Hooimeijer,  Eva Rettenbacher,  Frans J. Smiers,  Marjet A. Stein-Wit,  Arian van der Veer,  Annemieke Verbaan,  Marjon H. Cnossen,  Karin Fijnvandraat, 
  • Pages: 1606-1609
  • First Published: 29 April 2024
Free Access

GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease

Ryan Sun,  Anand Srivastava,  Vimal K. Derebail,  Jin Han,  Robert E. Molokie,  Victor Gordeuk,  Santosh L. Saraf, 
  • Pages: 1610-1612
  • First Published: 24 April 2024
Free Access

Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha-thalassemia

G. Lugthart,  E. J. T. Verweij,  C. L. Harteveld,  R. N. G. B. Tan,  M. F. C. M. Knapen,  F. Slaghekke,  M. C. Haak,  A. B. Mohseny,  F. J. Smiers, 
  • Pages: 1613-1615
  • First Published: 24 April 2024
Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha-thalassemia

Intra-uterine reduction of Hb Bart's only reached with exchange transfusions.

Free Access

Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study

M. Michel,  M. Saïr,  E. Rivière,  G. Moulis,  T. Comont,  N. Costedoat-Chalumeau,  C. Pouchelon,  D. Boutboul,  A. Benyamine,  A. Bert,  P. -Y. Jeandel,  S. Hamrouni,  N. Belfeki,  H. Lobbes,  A. Dossier,  D. Gobert,  M. Mahevas,  B. Godeau,  Y. Gallien,  M. Ebbo, 
  • Pages: 1616-1619
  • First Published: 14 May 2024
Free Access

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations

Petra Langerbeins,  Adam Giza,  Sandra Robrecht,  Paula Cramer,  Julia von Tresckow,  Othman Al-Sawaf,  Anna Maria Fink,  Moritz Fürstenau,  Arnon P. Kater,  Ellen van der Spek,  Carsten Utoft Niemann,  Caspar da Cunha-Bang,  Eugen Tausch,  Christof Schneider,  Stephan Stilgenbauer,  Kirsten Fischer,  Michael Hallek,  Barbara Eichhorst, 
  • Pages: 1620-1623
  • First Published: 17 May 2024
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations

Free Access

Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis

Aseel Alsouqi,  Gulrayz Ahmed,  Juntian Wang,  Giulio Cassanello,  Aniko Szabo,  Alexandra E. Rojek,  Peter A. Riedell,  Farrukh Awan,  Laura Samples,  Mazyar Shadman,  Marie Hu,  Veronika Bachanova,  William Wesson,  Nausheen Ahmed,  Madiha Iqbal,  Mohamed A. Kharfan-Dabaja,  Michael Scordo,  P. Connor Johnson,  Yi-Bin Chen,  Sawa Ito,  Mehdi Hamadani,  Matthew Frigault, 
  • Pages: 1624-1627
  • First Published: 20 May 2024
Free Access

Clinical and biological characterization of involvement of nasal-associated lymphoid tissues in chronic lymphocytic leukemia

Thimali Ranaweera Arachchige,  Catherine Mendiburu,  Antoine Martin,  Carole Fleury,  Elisabetta Dondi,  Rémi Letestu,  Virginie Eclache,  Fanny Baran-Marszak,  Florence Cymbalista,  Gregory Lazarian, 
  • Pages: 1628-1631
  • First Published: 10 May 2024
Free Access

BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis

Camille Kockerols,  Peter J. M. Valk,  Stéphanie Dulucq,  Franck-Emmanuel Nicolini,  François-Xavier Mahon,  Ehab Atallah,  Michael J. Mauro,  Jerald P. Radich,  Simona Bernardi,  Domenico Russo,  Mirko Farina,  Silvia Mori,  Carlo Gambacorti-Passerini,  Ivan Civettini,  Liu Lu,  David Yeung,  Susan Branford,  Gioia Colafigli,  Massimo Breccia,  Pauline Hogenbirk,  Joost van Rosmalen,  Jan J. Cornelissen,  Peter E. Westerweel, 
  • Pages: 1632-1635
  • First Published: 20 May 2024
Free Access

Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia

Tamer Othman,  Shanpeng Li,  Jianying Zhang,  Hoda Pourhassan,  Vaibhav Agrawal,  Dat Ngo,  Jason Chen,  Leonardo Farol,  Firoozeh Sahebi,  Karamjeet Sandhu,  Ricardo Spielberger,  Guido Marcucci,  Stephen J. Forman,  Anthony S. Stein,  Ryotaro Nakamura,  Vinod Pullarkat,  Matthew Mei,  Ibrahim Aldoss,  Paul Koller, 
  • Pages: 1636-1639
  • First Published: 27 May 2024
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia

Improved first progression-free survival following allogeneic hematopoietic cell transplantation relapse with the use of immunotherapy.

Free Access

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study

Jan Philipp Bewersdorf,  Shai Shimony,  Rory M. Shallis,  Yiwen Liu,  Guillaume Berton,  Eva J. Schaefer,  Amer M. Zeidan,  Aaron Goldberg,  Eytan Stein,  Guido Marcucci,  Rebecca P. Bystrom,  R. Coleman Lindsley,  Evan C. Chen,  Jorge Ramos,  Anthony Stein,  Vinod Pullarkat,  Ibrahim Aldoss,  Daniel J. DeAngelo,  Donna S. Neuberg,  Richard M. Stone,  Sylvain Garciaz,  Brian Ball,  Maximilian Stahl, 
  • Pages: 1640-1643
  • First Published: 15 May 2024
Free Access

Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis

Emeline Voirin,  Anne Bouvier,  Isabelle Plo,  Léa Durix,  Annaëlle Beucher,  Stephane Giraudier,  Valérie Ugo,  Jean-François Brasme,  Damien Luque Paz, 
  • Pages: 1644-1646
  • First Published: 16 May 2024
Free Access

Pregnancy in acquired bone marrow failure syndromes: Antenatal management and maternal and fetal outcomes

Marta Bortolotti,  Roochi Trikha,  Sarah Salter,  Joanna Large,  Evangelia Vlachodimitropoulou,  Shreyans Gandhi,  Wilma Barcellini,  Jemma Johns,  Bruno Fattizzo,  Austin Kulasekararaj, 
  • Pages: 1647-1650
  • First Published: 15 May 2024
Free Access

BCR-ABL testing in the evaluation of neutrophilia

Caleb J. Smith,  Gordon J. Ruan,  Lindsey Ann Kluck,  Mackenzie Maberry,  Ronald S. Go, 
  • Pages: 1651-1654
  • First Published: 17 May 2024
Free Access

Moderate–severe beta-thalassemia intermedia phenotype caused by sextuplicated alpha-globin gene allele in two beta-thalassemia carriers

Ahlem Achour,  Jeroen Knijnenburg,  Tamara Koopmann,  Amir Raz,  Marc Tischkowitz,  Thomas D. Coates,  F. Baas,  C. L. Harteveld, 
  • Pages: 1655-1658
  • First Published: 30 May 2024

CORRECTION

Free Access

Correction to “Benefit of axicabtagene ciloleucel vs chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy”

  • Page: 1659
  • First Published: 07 May 2024

Free Access

Correction to “Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials”

  • Page: 1660
  • First Published: 11 June 2024